Book contents
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Chapter L
from Drugs: An A–Z Guide
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Summary
Labetalol is a combined alpha- and beta-adrenoceptor antagonist. The proportion of beta blockade to alpha blockade when given orally is 3:1, and 7:1 when given IV. It lowers the blood pressure by blocking alpha adrenoceptors in arterioles and thereby reduces the peripheral resistance. Concurrent beta blockade protects the heart from reflex sympathetic drive, normally induced by peripheral vasodilatation.
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 174 - 190Publisher: Cambridge University PressPrint publication year: 2025